Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy

Sponsor
Fondazione EMN Italy Onlus
Study ID
NCT05393024
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Belantamab mafodotin — DRUG
    MMRR patients included in Named Patient Program e Expanded Access Program

Study Details

This is a retrospective/prospective observational study evaluating the efficacy and safety of Belantamab Mafotidin as a single agent in patients with Multiple Myeloma Relapse/Refractory (MMRR) treated in clinical pratice under compassionate use

Key Dates

Start date
Jul 22, 2022
Status verified
Jan 2025
Primary completion
Aug 12, 2024
Completion
Aug 12, 2024

Study Design

Enrollment
78 participants (actual)

Arms

  • Arm: Belantamab Mafoditin
    MMRR patients included in Named Patient Program and Expanded Access Program

Primary Outcome Measure

Best response or minimal response [ Time Frame: 1 year ]

Related Studies